

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K/A

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported) October 16, 2006

CytoDyn, Inc.

(Exact name of registrant as specified in its charter)

Colorado

000-49908

75-3056237

(State or other jurisdiction
of incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

227 E. Palace Ave, Suite M, Santa Fe, NM 87501

(Address of Principal Executive Offices) (Zip Code)

(505) 988-5520

(Registrant's telephone number, including area code)

(Former Name or Former Address, if Changed Since Last Report)

Item 4.02 (b)

On October 3, 2006 the company's audit committee dismissed our auditors Cordovano and Honeck LLP, as reported in the Current Report on Form 8-K filed on October 6, 2006.

On October 16, 2006 our new auditors Pender Newkirk & Company informed our Corporate Secretary and Vice President that they identified a misstatement in the financial statements filed as part of our Annual Report on Form 10KSB for the fiscal year ended May 31, 2006, as amended on September 1, 2006 (the "Form 10KSB-A"). The misstatement related to the accounting for the conversion option on certain convertible notes payable, which were initially accounted for as a derivative liability. This derivative liability has been restated to be correctly accounted for as a beneficial conversion feature and included as a component of additional paid-in capital. As a result, Pender Newkirk has stated that the financial statements accompanying the Form 10KSB-A should not be relied upon. We will therefore amend our 10KSB-A immediately to correctly characterize this accounting.

The company's authorized officers did discuss the matters disclosed in this report with independent auditors from Cordovano & Honeck and our new auditors at Pender Newkirk. The discussions led to the disclosures as filed in this report. The authorized officers also communicated the matters disclosed with the audit committee. The officers and audit committee reviewed the disclosures as filed with the Commission and are fully aware of the matters disclosed. The officers, audit committee members and independent auditor are all in agreement with the disclosures filed.

Our auditors have provided a letter which is attached as an Exhibit concurring with the disclosures filed herein.

Item 9.01 Financial Statements and Exhibits.

(c) Exhibits.

Exhibit Number	Description
23.1	Consent of auditors Pender Newkirk & Company, LLP

SIGNATURE

Pursuant to the requirements of Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CytoDyn, Inc.

Date: October 20, 2006

/s/ Allen D. Allen

Allen D. Allen
President

Exhibit 23.1

Pender Newkirk and Company, LLP
100 South Ashley Drive
Suite 1650
Tampa, Florida 33602
(813) 229-2321 Phone
(813) 229-2359 Fax

October 23, 2006

Securities and Exchange Commission
450 Fifth Street, NW
Washington, D.C. 20549

Re: CytoDyn, Inc.

Commissioners,

We are the principal accountants for CytoDyn, Inc. We have read CytoDyn, Inc.'s statements which we understand will be filed with the Commission pursuant to Item 4.02 (b) of Form 8-K. We agree with the statements concerning our Firm in such Form 8-K.

Very truly yours,

/s/ Pender Newkirk & Company LLP

Pender Newkirk and Company, LLP